Skip to main content
. Author manuscript; available in PMC: 2020 Jun 7.
Published in final edited form as: J Cell Physiol. 2019 May 9;234(12):22242–22259. doi: 10.1002/jcp.28792

FIGURE 2.

FIGURE 2

IL-17A induces TRAF3IP2-dependent MMP-13 expression and activation, and MMP-13-dependent SMC migration. (a) IL-17A induces time-dependent and TRAF3IP2-mediated MMP-13 mRNA expression. TRAF3IP2 expression was targeted as in Figure 1. (b,c) IL-17A induces MMP-13 protein expression and activity as analyzed by immunoblotting and enhanced fluorometric activity assay. (d) Pharmacological inhibition of MMP-13 by CL92198 and WAY175203 reduced IL-17A-induced MMP-13 activity. DMSO is used as a vehicle control (e). IL-17A mediated SMC migration reduced by either pharmacological inhibition or lentiviral shRNA-mediated knockdown of MMP-13. (f) shRNA-mediated knockdown of MMP-13 expression was confirmed by immunoblotting. (b,f) The intensity of immunoreactive bands from three independent experiments is semiquantified and summarized in the bottom (b) or right-hand side panels (f). Data represent mean ± SE. DMSO: dimethyl sulfoxide; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GFP: green fluorescent protein; IL: interleukin; MMP-13, matrix metalloproteinase-13; SMC: smooth muscle cell; TRAF3IP2: TRAF3 Interacting Protein 2. *p < at least 0.01 versus untreated; p < at least 0.05 versus IL-17A